Digital Dose Inhalers Market (Product: Metered Dose Inhalers and Dry Powder Inhalers)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Digital Dose Inhalers market was valued at USD 2.28 billion in 2021 and it is expected to hit around USD 7.30 billion by 2030 with a CAGR of 12.9% during the forecast period 2022 to 2030.

Digital dose inhalers are advanced, smart devices intended to treat and manage drug delivery for various respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Digital dose inhalers are used to provide a simple, accurate, and reliable dose counter, which enables patients to track adherence to their therapy. Increase in patient population, adoption of novel technologies, and surge in research & development in developed and developing countries are driving the global digital dose inhalers market. Furthermore, rise in prevalence of respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disorder) across the globe and increase in geriatric population are projected to drive the global digital dose inhalers market in the next few years. Thus, demand for digital inhalers for chronic obstructive pulmonary disease is anticipated to increase substantially across the globe. Introduction of data integration with EHR (electronic health records) or EMR (electronic medical records) is a major trend in the global digital dose inhalers market. However, management of chronic airway diseases is 10% medication and 90% education. Inability of patients to effectively use inhaler devices can be largely ascribed to deficiencies in clinicians’ knowledge of inhaler techniques. Thus, lack of knowledge, awareness, and training required to instruct patients in proper usage of digital inhalers is restraining the global digital dose inhalers market.

Emerging economies such as India, China, Brazil, and Mexico offer significant opportunities in the global digital dose inhalers market. Presence of large geriatric population; government initiatives to improve healthcare sector; rise in research & development activities; and increase in pollution, allergens, and occupational dust are factors driving the market in these countries. The highest rate of hospitalization in India is for cardiac and respiratory problems, and for asthma in Bangladesh. In 2020, the WHO estimated geriatric population of around 1,000 million, with 700 million of them living in developing countries. This offers lucrative opportunities for market players.

Report Scope of the Digital Dose Inhalers Market

COVID-19 Impact on Digital Dose Inhalers Market

The outbreak of COVID-19 has had a positive effect on the global digital dose inhalers market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Hence, COVID-19 has led to a surge in demand for these products. Furthermore, worsening of the pandemic situation affected the supply and demand gap and increased the demand for digital dose inhaler devices. Patients with asthma are at a higher risk of contracting COVID-19. As the virus continues to spread, hospitals are increasingly using metered dose inhaler. COVID-19 is sparking fear of medication shortage and panic buying, which could lead to a shortage of critical inhalers. Therefore, increase in panic buying, high risk of COVID-19 among patients with respiratory diseases, and high demand and supply gap are driving the global digital dose inhalers market.

Increase in Awareness and Penetration Augmenting Demand for Metered Dose Inhalers

In terms of product, the metered dose inhalers segment accounted for major share of the global digital dose inhalers market in 2021. This can be ascribed to the rise in penetration and product launch of metered dose inhalers; and increase in awareness about these products among patients. According to NCBI, the inherent multi-dose nature of MDIs makes them more affordable than most competing inhalation delivery systems. Thu, metered dose inhalers are considered highly popular inhalers to treat local respiratory diseases such as asthma and COPD.

Increase in regulatory approvals is driving the metered dose inhalers segment. For instance, in December 2018, AstraZeneca received approval from the European Commission (EC) for Bevespi Aerosphere, which is used in a pressurized metered dose inhaler (pMDI) indicated as maintenance dual bronchodilator treatment in adult patients with COPD. This approval enabled the company to add a technologically advanced product to its existing product offerings for patients in Europe.

High Prevalence of Asthma to Boost Digital Dose Inhalers Market

In terms of application, the asthma segment accounted for significant share of the global digital dose inhalers market in 2021. This can be ascribed to high prevalence and product launches. According to the WHO, asthma was a major non-communicable disease in 2019. Asthma affected an estimated 262 million people and caused 455,000 deaths in 2019. According to the Asthma and Allergy Foundation of America, more than 26 million people in the U.S. suffer from asthma. Incidence of asthma has been increasing since the early 1980s in all ages, sexes, and racial groups.

Rise in launch of digital inhalers for asthma is driving the asthma segment. For instance, in January 2017, Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) approved two of its products for adolescent and adult patients with asthma. These products, i.e. AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick breath-activated, multi-dose dry powder inhaler (mDPI), which is also used with other approved medicines from Teva’s respiratory inhaler product portfolio.

Regional Outlook of Global Digital Dose Inhalers Market

North America dominated the global digital dose inhalers market in 2021. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of COPD and asthma in the U.S. and Canada; well-established healthcare infrastructure; and high risk of lifestyle-related diseases. Furthermore, increase in trend of smoking in North America is propelling the risk of asthma. Smoking is directly responsible for around 90% of lung cancer deaths and nearly 80% of deaths caused by chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis. Additionally, robust product pipeline of key players is projected to drive the global digital dose inhalers market in North America.

Asia Pacific is anticipated to be the fastest growing market for digital dose inhalers during the forecast period. China dominated the digital dose inhalers market in the region in 2021. The digital dose inhalers market in India is likely to grow at a high CAGR during the forecast period. According to Lung India, a recent Indian study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis (INSEARCH) conducted on 85,105 men and 84,470 women from 12 urban and 11 rural sites in India, the rate of prevalence of asthma in India stands at 2.05% among individuals aged over 15 years, with a burden of around 18 million asthma patients across the country.

The digital dose inhalers market in Latin America and Middle East & Africa is likely to grow at a decent CAGR owing to the increase in respiratory disease patient pool and focus of manufacturers on the development of novel products.

Key Developments in Global Digital Dose Inhalers Market

• In March 2022, the U.S. Food and Drug Administration gave the approval for the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions to Mylan Pharmaceuticals, Inc.
• In July 2019, Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) approved “ProAir Digihaler” inhalation powder, the first and only digital inhaler with built-in sensors, which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. ProAir Digihaler is used for the treatment or prevention of bronchospasm in patients aged four years and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB) in patients aged four years and older.
• In February 2019, 3M announced that it had completed the acquisition of M*Modal’s technology business for a total enterprise value of US$1 Bn. M*Modal’s technology business provides cloud-based, conversational artificial intelligence (AI)-powered systems. This is likely to expand the capabilities of 3M’s Health Information Systems business.

Some of the prominent players in the Digital Dose Inhalers Market include:

• Novartis AG
• AstraZeneca
• Glenmark
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• 3M
• Sensirion AG Switzerland
• AptarGroup, Inc.
• Cipla, Inc.
• H&T Presspart Manufacturing Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Digital Dose Inhalers market

• Product
• Metered Dose Inhalers
• Dry Powder Inhalers
• Application
• Asthma
• COPD (chronic obstructive pulmonary disease
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Digital Dose Inhalers industry analysis from 2022 to 2030 to identify the prevailing Digital Dose Inhalers industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Digital Dose Inhalers industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Digital Dose Inhalers industry trends, key players, market segments, application areas, and market growth strategies.